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Inflammatory bowel diseases (IBD) typically affect
patients in their reproductive years. It has been shown
that reproductive issues are of key concern to IBD
patients,1 especially women.2 In this respect, it is
important to note that IBD patients remain voluntary
childless more frequently than non-IBD controls.1,3,4 A
recent study reported that IBD patients refrain from having
children due the concerns about the adverse reproductive
outcome.1 Fear of side-effects of the medication on the
child and medical advice given by physicians, were the
most important reasons for voluntary childlessness in this
study.
The treatment of IBD patients wishing to conceive is
surrounded with uncertainties both for the parents to be and
the treating physician. This guideline is developed to
address these uncertainties and to promote a European
perspective on reproduction in inflammatory bowel disease
patients.The strategy to reach consensus involved the following
steps:
1. The development of questions that should be covered by
these pregnancy guidelines. Participants were asked to
review these questions and when necessary to adjust or
add questions.
2. The participants met in London in November to agree on
the questions
3. The participants performed a systematic literature search
of their topic with the appropriate key words using
Medline/Pubmed and the Cochrane database, as well as
their own files. The evidence level was graded (Table 1)
according to the Oxford Centre for Evidence-Based
medicine 5.
4. Provisional statements of the participants were written
and the participants met in Prague in February 2010 to
agree on the statements. This was done by projecting the
statements and revising them on screen until a consensus
was reached. Consensus was defined as agreement by
Table 1 Safety of IBD drugs in pregnancy (ECCO rating).
Safe Probably safe Contraindicated
Oral 5-Aminosalicylates Infliximab Methotrexate
Topical 5-Aminosalicylates Adalimumab Thalidomide
Sulfasalazine Certolizumab 6-thioguanine
(no data)Corticosteroids Cyclosporin
Azathioprine Tacrolimus
6-Mercaptopurine Budesonide
Metronidazole
Ciprofloxacin
495European evidenced-based consensus on reproduction in inflammatory bowel diseaseN80% of the participants. Each recommendation was
graded as stated above.
5. The final document on each topic was written by the
designated participants. Consensus guideline statements
in bold are followed by comments on the evidence and
opinion. Statements are intended to be read in context
with qualifying comments and not to read in isolation. The
final document was edited by the first author. In some
areas the level of evidence is generally low, which
reflects the lack of prospective trials in this specific
area. Consequently expert opinion is included where
appropriate.
6. This document includes the ECCO opinion on drug safety
during pregnancy and lactation. This approach is carefully
chosen because the FDA made an announcement in May
2008, stating that they will replace the A, B, C, D, and X
classification system with a narrative framework consist-
ing of 3 sections although the system is easy to use, it
might oversimplify the complexity of weighing risks to the
fetus against the need to adequately manage maternal
medical conditions 6. The system does not fully address
the fact that the benefits of treatment of some conditions
(e.g., diabetes, asthma, pregnancy-induced hyperten-
sion, and psychiatric conditions) might outweigh the risk
of fetal drug exposure.2. Fertility in IBD
2.1. Influence of disease activity on fertility in
females and malesECCO Statement 2 A
There is no evidence that ulcerative colitis or inactive
Crohn's disease affects fertility [EL3a, RG B]; however
active Crohn's disease may lead to reduced fertility.
Therefore it is advisable to strive for clinical remission
to optimise the chances of conception [EL3b, RG B].Patients with quiescent IBD are as fertile as the general
population. Patients with IBD have fewer children than the
general population, but this may partly be because of
voluntary childlessness.7,8 It is suggested that active Crohn's
disease (CD) reduces fertility by several mechanisms,including inflammation involving the fallopian tubes and
ovaries and perianal disease causing dyspareunia.9
2.2. Influence of medication on fertility and
conception in IBD patientsECCO Statement 2 B
There is no evidence that medication for IBD affects
fertility in females [EL4, RG C]. In males sperm quality
may be affected by sulphasalazine, methotrexate, and
infliximab [EL4, RG C].Sulfasalazine therapy causes a reversible decrease in
sperm motility and count in male patients. The effect is dose
related and it is unaffected by supplemental folic acid.10–13
Azathioprine (AZA) did not influence sperm quality in 18 male
IBD patients who used AZA at least 3 months.14 Methotrexate
(MTX) given for psoriasis produces oligospermia, this will
improve within a few months after stopping the drug.15
Infliximab (IFX) seems to affect semen quality by reducing
motility in a small group of patients; however sperm
concentration increased after infusion.16,17 The outcome of
10 pregnancies indirectly exposed to IFX through the male
partner resulted in 9 lives births, 1 miscarriage and no
congenital malformations were reported.17
For anti-TNF alpha it is unknown whether the fetus will
be affected by exposure to anti-TNF alpha through semen
and therefore barrier methods are advised during pregnancy
[EL 5, RG D].
2.3. The influence of abdominal surgery on fertility
in malesECCO Statement 2 C
Pelvic surgery may lead to impotence or ejaculatory
problems in men [EL4, RG C].Men who undergo ileoanal pouch surgery for ulcerative
colitis (UC) may experience retrograde ejaculation and
erectile dysfunction.18–20 However, these studies have
shown that overall there is no change or even an improve-
ment in sexual function post surgery.18–21 The effect of
preservation or improvement of sexual function after surgery
on fertility rates in men has not been studied.
2.4. The influence of abdominal surgery on fertility
in femalesECCO Statement 2 D
Pelvic, and to a lesser extent, abdominal surgery for
IBD increases the incidence of subfertility in females
[EL2a, RG B].
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cessful to conceive within a year) has an increased
incidence amongst women with IBD who have undergone
surgery.8,9,18,22–26 A systematic review concluded that
the fertility of women with UC was reduced after
restorative proctocolectomy27 and a meta-analysis found
that ileal pouch-anal anastomosis (IPAA) conferred a
three-fold increased risk of infertility compared to
medical management.28 Studies have demonstrated a
high rate of hydrosalpinx, destruction of fimbria, and
tubal obstruction following pelvic surgery29 and this is
the most likely mechanism for subfertility after surgery.
There is a large amount of literature on the use of
laparoscopic IPAA, however, there are no studies that
show improved fertility following a laparoscopic rather
than a conventional approach. Likewise there are no
data to support the approach of subtotal colectomy with
rectal stump and ileostomy during the childbearing
years and then creating an IPAA later in life to help
reduce infertility rates. The drawbacks of the latter
procedure include rare ileostomy complications during
pregnancy such as obstruction and stoma related
problems.30,313. Pregnancy and delivery outcome of mothers
3.1. The influence of pregnancy on the activity of
inflammatory bowel diseasesECCO Statement 3 A
If conception occurs at a time of quiescent dis-
ease the risk of relapse is the same as in non-
pregnant women [EL5, RG D]. Conception occur-
ring at a time of active disease is associated with
persistent activity during pregnancy [EL3b, RG B].
Pregnancy might affect the natural course of IBD
[EL2, RG B].When conception occurs during a period of remission
about a third of patients relapse during pregnancy which
is similar to that expected in non-pregnant CD patients
over a period of nine months.32–35 On the other hand, if
conception occurs at a time of active disease, two thirds
have persistent activity and of these, two thirds will
deteriorate. This underscores the importance of advising
patients to conceive at a time when disease is in
remission.36–38 It seems that pregnancy influences the
overall course of IBD positively, because as parity
increases, the need for surgical intervention decreases.
Furthermore patients with a previous pregnancy require
fewer resections and the interval between operations
tends to be longer when compared with nulliparous
women with CD.39,40 Mothers with CD seem also to have
a lower relapse rate in the years after pregnancy,
compared with the years before pregnancy but specific
confounders such as smoking have not been investigated
or ruled out in multivariate analyses.41,42 Pregnancy hasan effect on the immune system, which may contribute
to these findings.353.2. The mode of delivery and outcomesECCO Statement 3 B
The mode of delivery should primarily be governed
by obstetric necessity and indications. However, a
multidisciplinary approach involving the gastroenter-
ologist and/or the colorectal surgeon is advocated
[EL 5, RG D].
ECCO Statement 3 C
An ileoanal pouch or an ileorectal anastomosis in
women with IBD is regarded as a relative indi-
cation for a caesarean section but the decision
should be made on an individual basis [EL 4, RG D].
Caesarean section should be preferred in active
perianal disease or recto-vaginal involvement [EL4,
RG C].
The mode of delivery should primarily be dictated by
obstetric necessity, but the decision should be combined
with the gastroenterologist and/or the colorectal surgeon
to give the obstetrician and patient a balanced view on
the consequences of a post partum sphincter/pelvic floor
impairment with respect to present and future bowel
function. Caesarean section is recommended in patients
with perineal disease or in case of rectal involvement.
Although some clinicians advocate caesarean section for
all CD patients it seems reasonable to allow vaginal
delivery for women with quiescent or mild disease as no
evidence can be found in the literature for either
approach.43,44 Episiotomy should be avoided if possible
because a high rate of perianal involvement has been
reported, but is better than an uncontrolled lacera-
tion.45 IPAA is regarded as an indication for caesarean
section.46–49 The reason being that a person with an
IPAA is borderline incontinent and depends much more
on an intact sphincter and pelvic floor function for
maintaining faecal continence compared with a person
having intact rectal functions. The reasoning could also
be applied to patients with an ileorectal anastomosis
although they have an intact rectal function they could
have loose stools and are at risk of recurrent disease and
further surgery. The literature is not unanimous on
this.45,50,51,52 There is a one in five risk that a woman
with UC will need a colectomy and may be a candidate
for an ileal pouch anal anastomosis during her fertile
period. The risk of sphincter injuries is highest at the
first delivery. Counselling a non-operated UC patient
with regard to mode of delivery must be on an individual
basis mainly adhering to obstetric principles. Patients
with a colostomy, ileostomy or continent ileostomy can
deliver vaginally, but if the obstetric risk is increased for
other reasons, there should be a low threshold for
caesarean section. A recent patient survey has indicated
that IBD patients have more problems with persisting
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controls.533.3. The risk of relapse after deliveryECCO Statement 3 C
There is no increased risk of a flare in the postpartum
period if women remain on their maintenance therapy
[EL 2c, RG C].About a third of IBD mothers experience a flare after
delivery54 but this risk is not significantly higher when
compared to the risk of having a flare while not having a
child. Patients with IPAA have a 20–30% chance of developing
disturbances of pouch function (increased bowel frequency
and a decrease in continence) in pregnancy and particularly
in the third trimester. These changes usually resolve
completely during the puerperium.46,51,55,564. Outcome of children
4.1. Risk of developing IBD with one or both parents
having IBDECCO Statement 4 A
Children from parents with IBD have an increased
risk of developing IBD. The risk is higher for
Crohn's disease (2–3%) than for ulcerative colitis
(0.5–1%) [EL3, RG B]. The highest risk appears
for children of whom both parents have IBD [EL4,
RG C].The familial occurrence of IBD is well-known. Around 5.5%
to 22.5% of patients with IBD have another family member
also affected with the disease.57,58 In fact, the most
important risk factor for IBD is having a family member
with the disease. The relative risk for a sibling of a CD patient
to become affected is 13 to 36, and for a sibling of a UC
patient this relative risk is 7–17. Translating this into
absolute numbers, hereby assuming an overall incidence in
Europe and North-America of 10 new cases per 100,000 for
UC and 5–6 new diagnoses per 100,000 for CD, this gives a
risk of only 2–3% for a sibling of a CD patient and 0.5–1% for a
sibling of a UC patient.59 The greatest risk appears for
children of whom both parents have IBD and was shown to be
above 30% at the age of 28 years.60 Patients with IBD and a
familial history tend to get their disease at an earlier age
than patients without a familial history and show an
increased concordance in disease type (CD or UC) and
probably also disease location.60-62 In contrast, the severity
of the disease does not differ between familial or sporadic
disease.4.2. Outcome of pregnancy and adverse outcome of
offspringECCO Statement 4 B
Women with IBD and in particular with Crohn's
disease may have an increased risk of adverse
pregnancy outcome [EL 2b, RG C]. These adverse
outcomes include low birth weight, preterm delivery,
and an increased frequency of Caesarean section
[EL 2, RG B]. Increased risk for adverse pregnancy
outcome is regardless of disease activity [EL 2b, RG
B] although in Crohn's disease the rate of preterm
delivery correlates with the severity of the disease
[EL 3b, RG D].
ECCO Statement 4 C
Adverse outcomes such as death, low APGAR scores,
seizures or admission to an intensive care unit [EL 2b,
RG B] are not significantly increased in babies born at
term. Whether the risk for congenital anomalies is
increased remains controversial due to large discre-
pancies in the literature [EL 2b, RG D].Women with IBD have an increased overall risk for adverse
pregnancy outcomes. The most consistently described are
preterm delivery (before 37 weeks of gestation) with a
relative risk of 1.87, and low birth weight (less than 2700 g)
with a relative risk of 2.1.38,61,63 Concerning delivery mode,
most studies have also shown significantly increased fre-
quency of Caesarean section, but is it not consistently clear
whether this is predominantly due to elective or emergency
intervention by caesarean section.33,37,38,64,65 Adverse preg-
nancy outcomes are more frequent in pregnant women with
CD, compared to UC.
Only few studies have looked at the influence of IBD on a
conception outcome (miscarriage) and on the rate of
complications of pregnancy and labour (abruption of
placenta, chorioamnionitis, eclampsia, placenta praevia,
premature and prolonged membrane rupture, ectopic
pregnancy). While the rate of abortion is increased, both,
spontaneous and induced, data on the frequency of
complications of pregnancy and labour are very inconsistent,
precluding a meaningful conclusion.33,37,64,65
Disease severity probably does have an impact on
pregnancy outcome. However, most of the studies did not
evaluate this effect, and the only recent studies that
specifically addressed the influence of CD activity, found
the 3.4 fold increase in the risk of preterm birth, but not in
low birth weight, low birth weight at term and in congenital
anomalies in women with active disease.66
Except for the prematurity (infants delivered before
37 weeks) and low birth weight, maternal IBD seems to have
no major adverse effects on the infant born at term. In these
infants the APGAR scores, death rate, hospitalization in the
intensive care unit, and seizures were not more common in
offspring of mothers with IBD. Concerning the rate of
congenital malformations, data is equivocal, mostly due
to inconsistencies in the diagnoses included and the
498 C.J. van der Woude et al.confounding influence of the used medications. However, UC
might carry a higher risk for congenital anomalies compared
to CD, particularly for selected anomalies such as: limb
deficiencies (OR 6.2), obstructive urinary malformations
(OR 3.3), and multiple congenital anomalies (OR 2.6).38,67-694.3. Effect of medication used for IBD treatment
during pregnancy on the health and development of
the infant, including the vaccination programmeECCO Statement 4 D
There are no published long term data on infant health
outcomes such as neurodevelopment, incidence of
childhood malignancies or increased risk for other
specific disorders with respect to foetal in utero drug
exposure [EL 5, RG D].
ECCO Statement 4 E
Current vaccination strategies with non-live vaccines
for infants who have been exposed in utero to anti-
TNF do not differ from those for unexposed infants as
no adverse effects have been reported, and responses
to vaccination were appropriate [EL4 RG D].
ECCO Statement 4 F
Live vaccines such as rotavirus, oral polio virus and
Bacille Calmette–Guerin (BCG) vaccination should be
provided when there is no detectable anti-TNF in the
blood — which is expected in most infants in the
second half of the first year [EL5 RG D]. To limit the
transport of the drug to foetus, timing of the last dose
of anti TNF therapy should be as early in the third
trimester of pregnancy as possible [EL5 RG D].As IFX is present in the circulation through the first
6 months of life, there are concerns about the immune
system development, rate of infections, and also possible
implications for the response to vaccination. So far, there
have been no reported adverse infectious events,70 and
immune responses to routine childhood vaccinations were
appropriate,71 as well as the response of adult patients
treated with adalimumab (ADA) to vaccination with pneu-
mococcal and influenza vaccination.72 Therefore, current
vaccination strategies with non-live vaccines for infants who
have been exposed to anti-TNF in utero do not differ from
those for unexposed infants. This does not apply for live
vaccines such as rotavirus, oral polio and Bacille Calmette–
Guerin (BCG) vaccinations which are contraindicated in
immune suppressed individuals. So far one case was reported
of a child from a mother exposed to IFX during pregnancy
that died at 4.5 months due to disseminated BCG infection
after receiving a vaccination at 3 months.73 Live vaccines can
be provided to infants only in the second half of the first
year, when it is expected that no detectable IFX or ADA arepresent, or when there are no detectable anti-TNF levels
measured in the infant. Also, timing of the last dose of IFX
and ADA should be as early in the third trimester as possible
to maintain remission but to limit transport to the
fetus.69,74,75 Whether this applies for Certulizumab pegol
needs to be investigated. The levels of other drugs used for
IBD treatment in infants (such as azathioprine) are probably
not elevated and will not influence vaccination programs,
however data are lacking.
5. Management of IBD during pregnancy
5.1. The influence of IBD activity on
IBD managementECCO Statement 5 A
Acute flares during pregnancy carry a high risk of
adverse outcome, and are best treated aggressively to
prevent these complications [EL 3a, RG C]. Appropri-
ate medical treatment of IBD (Table 1) should be
continued in those patients who wish to conceive
in order to reduce the risk of flares during pregnancy
[EL 5, RG D].Several studies have demonstrated that most pregnancies
in women with IBD will be uncomplicated, if the patient is in
remission or has only minor disease activity at the time of
conception.76–78 A meta-analysis by Miller with more than
1300 female patients with UC and over 700 patients with CD
clearly demonstrated that normal pregnancies are observed
in 83% of women with CD (71–93% in individual studies) and in
85% of women with UC (76–97% in individual studies).79
Malformations were observed in about 1% of all pregnancies
and also the frequency of spontaneous abortions and still
births were in the same range as observed in the healthy
normal population. In contrast, several studies demonstrate
that the frequency of normal pregnancies is reduced and the
frequency of adverse outcomes of pregnancy is increased,
when pregnancies take place in phases with active inflam-
matory bowel disease.80–84 Moreover, compared to pregnant
IBD patients with inactive disease, women with a relapse
during pregnancy have infants with significantly shorter
gestation time and lower birth weight.32,62,82,83 Therefore,
the flares of active disease in pregnant patients have to be
treated aggressively, and it is best if conception occurs
during remission.
5.2. Medical treatment of IBD and congenital
malformationsECCO Statement 5 B
Most drugs used for the treatment of IBD are
considered to be of low risk during pregnancy;
however, methotrexate and thalidomide, are contra-
indicated [EL3, RGB].
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The use of 5-ASA derivatives, corticosteroids and
biologicals is not significantly associated with mal-
formations or adverse outcomes in pregnant IBD
patients and their offspring [EL3, RG C]. Patients
treated with sulfasalazine should be supplemented
with folic acid [EL3, RG C]. In cases of relapse, 5-ASA
and corticosteroids are preferred therapy.
ECCO Statement 5 D
Due to lack of potential adverse drug effects,
exclusive enteral nutrition can be considered as an
option [EL5 RG D].
ECCO Statement 5 E
In the majority of patients, maintaining remission with
medical treatment outweighs the potential risks of
adverse drug effects (EL3, RGB). However, the
benefits and the risks must be discussed with the
patient and management decisions have to made on
an individual basis [EL5, RGD].
For a summary of safety aspects of frequent IBD
medications used during pregnancy84,85 and current ECCO
recommendation categories see Table 1.
5.2.1. Aminosalicylates, sulfasalazine
Sulfasalazine and all aminosalicylates are considered safe.
Case series, population-based cohort studies,37,86–89 and
two meta-analysis39,90 did not demonstrate an increased risk
for early pregnancy adverse outcomes such as miscarriage
and ectopic pregnancy. Some trials have demonstrated a
higher rate of premature birth, stillbirth, and low birth
weight, however, the confounding factor of active disease is
difficult to delineate. Both animal and human data and the
recent meta-analysis90 did not demonstrate teratogenic
effect. A small increase in risk of congenital malformations
has only been shown in the meta-analysis by Cornish et al.,
whereby it could have been the result of disease itself.39 As
sulfasalazine treatment interferes with folate absorption,
supplementation is recommended (2 mg/day of folate).
5.2.2. Corticosteroids
All corticosteroids (systemic, oral and topical) can cross the
placenta to the fetus but are rapidly converted by placental
11-hydroxygenase to less active metabolites, resulting in low
foetal blood concentration. As short-acting prednisone,
prednisolone and methylprednisolone are more efficiently
metabolized by the placenta and therefore reach lower
concentrations in the fetus than the longer-acting dexameth-
asone and betamethasone, the former molecules are pre-
ferred for the treatment of maternal conditions necessitating
glucocorticosteroids. Adverse effects on pregnancy outcome,
shown in animal studies, have not been confirmed in
humans.33,37,38 However, the risk for orofacial malformations
(cleft lip/palate) is increased in offspring of mothers receiving
steroids in the first trimester of pregnancy,91-93 though this
increased risk is small, and not confirmedby all studies.94 Also,
there are case reports of neonatal adrenal suppression due to
the use of corticosteroids in the late pregnancy of woman withIBD.95 There is just one case series of eight CD patients treated
with budesonidewhich did not find an increased risk of adverse
pregnancy outcome.96
5.2.3. Azathioprine (AZA) and 6-mercaptopurine (6-MP)
AZA and its metabolite 6-MP are purine analogues which
interfere with the synthesis of adenine and guanine
ribonucleotides. AZA crosses the placenta, and though it
hardly enters fetal circulation, metabolites have been
determined in comparable levels in maternal and foetal
red blood cells.97,98
Fetal exposure to AZA and 6-MP has been reported in
several hundreds of cases. Most studies demonstrated the
safety of thiopurines in females and males as no increased
risk of malformations in the newborn occurred.37,87,99–101
The most commonly cited pregnancy adverse outcomes are
increased rate of spontaneous abortions, preterm delivery
and low birth weight.99,102 Again, in the majority of
studies the adverse birth outcome could have been caused
by the underlying disease rather than by the use of AZA or
6-MP.103 Further risks for newborns and infants, described
in a few cases, are immunological and haematological
abnormalities, and chromosomal aberrations, caused prob-
ably by immunosuppression.100 For 6-thioguanine (6-TG) it
is reported that it passes the placenta,104 further safety data
are not available and therefore 6-TG during pregnancy in IBD is
not advised.
5.2.4. Cyclosporin and tacrolimus
Both, cyclosporin and tacrolimus are widely used for
treatment and prevention of graft versus host reaction
after bone marrow transplantations, and to restrain rejec-
tion after solid organ transplantation. Therefore most of
data on pregnancy outcome are derived from these patients.
For cyclosporin, a meta-analysis of 15 studies with 410
pregnant patients did not find an increased rate of
congenital malformations.105 Similar, but fewer, data exist
for tacrolimus.106
Evidence on the use of cyclosporin in IBD is limited to
small series of women that had severe relapses during
pregnancy.32,107 With tacrolimus just a single case report of
UC patient was published.108 No congenital malformations
were described; the outcomes were complicated with
prematurity and low birth weight, but it is very difficult to
differentiate the impact of severe disease from the effect of
drug itself.
5.2.5. Methotrexate and thalidomide
Both drugs are teratogenic and contraindicated in pregnancy
and therefore barrier methods to prevent pregnancy during
therapy with MTX are advised.
Though normal pregnancy outcomes were reported,109
exposure to MTX, particularly during the first trimester, may
result in abortions, growth retardation, foetal loss, and
congenital malformations, including craniofacial anomalies,
limb defects and CNS abnormalities.110 If conception should
accidentally occur, therapeutic abortion should be dis-
cussed, but not necessarily performed. Prospective mothers
should be instructed to stop MTX immediately and start high
dose folate replacement. The intracellular metabolites of
MTX, methotrexate polyglutamates, have a long half life and
take about six weeks to reach steady state or to completely
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both females and males, at least for 3–6 months before
trying to conceive. Use of thalidomide has been associated
with major foetal malformations involving limbs, ears, eyes,
neural tube defects, and with neonatal mortality rate of
40%.111
5.2.6. Biologic therapy
IFX and ADA both are IgG1 antibodies, and can cross
placenta, particularly in the second and third trimester.74
Therefore, IFX and ADA are expected to be present in fetal
circulation and in infants for several months after birth. For
ADA this has not been documented yet, but seems
presumable. Concerning IFX, detectable levels were found
in a case report112 and also in 8 healthy infants delivered
after pregnancies during which mothers were receiving IFX
every 8 weeks, with the last infusion being delivered at the
mean time of 66 days before birth. At birth, levels were, as
expected, higher in infants, and were measurable for 2 to
7 months.113 This case series, as well as the evidence coming
from the TREAT registry with 117 pregnant mothers exposed
to IFX114 and from IFX Safety Database where data are
available for 96 women with direct exposure to IFX17 suggest
that IFX is of low risk in pregnancy, both for the early and late
outcomes, and does not seem to be a teratogenic.
For ADA three case reports were published on 3
pregnancies in patients with CD. No complications occurred
in any of these pregnancies and all the babies were
developing normally at 6 months.115–117 Interestingly adali-
mumab 40 mg every other week or weekly was administered
in 14 women with previous recurrent spontaneous abortion
to prevent miscarriage. Four pregnancies resulted in
miscarriage; in the other 10 pregnancies no abnormalities
1occurred.118
Certolizumab pegol is a PEGylated Fab′ fragment of a
humanized anti-TNFα monoclonal antibody. Fab′ fragments
cross the placenta by passive diffusion, unlike the active
transfer of IgG1 antibodies, so the rates of transfer across the
placenta in the third trimester are likely to be lower than IFX
or ADA. A study of pregnant rats receiving a murinized IgG1
antibody of TNFα and a PEGylated Fab′ fragment of this
antibody, demonstrated much lower drug concentrations in
the infant rat and breast milk with the Fab′ fragment,
compared to the full antibody.119 The experiences with
certolizumab pegol are more limited, but experimental data
in animals and first clinical data do not reveal an increased
teratogenic risk in humans.120
5.2.7. Metronidazole, cipropfloxacin
Metronidazole and the quinolones have limited benefit for
long term treatment of IBD. Short courses of these medica-
tions may be beneficial in the treatment of pouchitis and
perianal disease and are low risk in the pregnant patient.
Metronidazole is used for treatment of active CD as well as
perianal disease. This medication does not increase risk of
spontaneous abortion or congenital anomalies,121,122 although
infants of women exposed to metronidazole in the second to
third months of pregnancy have shown higher rates of cleft lip
with or without cleft palate.
Human studies with ciprofloxacin have not shown an
increase in spontaneous abortion or congenital abnormality
incidence.123 However, animal studies demonstrate muscu-loskeletal abnormalities induced by this medication class.124
Fluroquinolones have a high affinity for bone tissue and
cartilage, and may cause arthropathies in children. Although
they are thought to have minimal risk overall, they should be
avoided in the first trimester.
5.3. Nutritional deficienciesECCO Statement 5 I
Nutritional deficiencies such as folate [EL 1a, RG A],
B12, iron and vitamin D [EL2a, RG B] should be
assessed and treated as required. Folic acid 1 mg
should be commenced in all IBD patients in anticipation
of a pregnancy [EL1a, RG A].
There are no specific nutritional recommendations in
pregnant women with IBD beyond control population or
specific situations (such as an obstructed CD patient). Scarce
reports in older literature addressed hyperalimentation as a
method of sustaining pregnancy in IBD patients. The data do
not justify specific recommendations. Folic acid supplemen-
tation before conception is recommended for all women125–131
and although data are lacking higher doses could be given in
women with known small bowel disease.
5.4. Surgery during pregnancyECCO Statement 5J
Indications for surgery in pregnant women with IBD are
the same as for non-pregnant patients: In UC the main
indication would be severe colitis not responding to
medical therapy. In Crohn's disease obstruction, perfo-
ration, haemorrhage, and abscess. In the severely ill
patient, continued illness is a greater risk to the foetus
than surgical intervention [EL4, RG C].Indications for surgery in pregnant women with IBD do not
differ much from non pregnant women. In severely ill
patients, continued illness is a greater risk to the foetus
than surgical intervention.132 In women with CD obstruction,
perforation, haemorrhage, or abscess are indications for
surgery and are no different to those for non-pregnant
women.77,132–134 Procedures have included proctocolecto-
my, hemicolectomy, segmental resection, and ileostomy. A
temporary ileostomy is generally preferred, to reduce the
risk of postoperative complications after primary anastomo-
sis.134 In the case of ulcerative colitis the indication for
surgery is severe disease not controlled by medical therapy
and urgent premalignant or malignant disease discussed on
an individual basis. With respect to timing of surgery during
pregnancy there is seldom room for a choice. Surgery is
relatively safe in all trimesters but there is some limited
series reporting on spontaneous abortion in the first
trimester and preterm labour when operation in the third
trimester.134
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6.1. Influence of lactation on disease activityECCO Statement 6 A
Lactation does not independently affect disease
activity in IBD [EL 2C RG C].
Lactationwas associatedwith an increase in disease activity
in one study; however medication cessation was a confounding
factor.135 More recently lactation was not associated with an
increased risk for a flare in either CD or UC.546.2. Medical treatment during lactationECCO Statement 6 B
5-ASA derivates are considered to be safe [EL 3b,
RGB]. Corticosteroids are considered to be safe [EL 4,
RG C]. Thiopurines are excreted in small amounts in
the breast milk. Thiopurines are probably safe;
however lactation needs to be discussed because of
unknown long-term side effects in the newborn with
immature liver metabolism. [EL4, RG C].
ECCO Statement 6 C
All anti-TNFsare likely tobeexcreted in thebreastmilk in
very small amounts. However, no adverse effects have
been reported in the small number of infants breastfed
bymothers on this therapy.With such little data, the use
of anti-TNFs in the breastfeeding mother needs to be
carefully discussed and if available consider drug and
antibody monitoring in milk and infants [EL5, RG C].
For a summary of safety aspects of frequent IBD
medications used during lactations and current ECCO
recommendation categories see Table 2.
Sulfasalazine is safe for breast feeding. The sulfapyridine
moiety is absorbed in minimal amounts and is excreted in
milk, however the milk: serum ratio is acceptable.136 The
safety of aminosalicylates has been confirmed in prospective
trials.137–139
As metronidazole140 and ciprofloxacin141 are excreted
into milk both drugs are not considered as appropriate during
the breastfeeding period.Table 2 Safety of IBD drugs during lacatation (ECCO rating).
Safe Probably safe
Oral 5-aminosalicylates Infliximab
Topical 5-aminosalicylates Adalimumab
Sulfasalazine Certolizumab
Corticosteroids (4 hour delay) Azathioprine
6-Mercaptopurine
TacrolimusPrednisone and prednisolone result in low human breast
milk concentrations. To minimise exposure, a 4 hour delay
after oral dosing could be recommended.142,143
Very small amounts of AZA/6-MP metabolites (nanomolar
concentrations of 6-methyl mercaptopurine and thiouric
acid) appear in breast milk a reported in several case
reports.144-146 There is a great interindividual variability in
the absorption and metabolism of azathioprine and 6-
MP147,148 that influences the exposure of the individual child.
Limited data suggest that infant exposure to tacrolimus
via milk is low and therefore this should be discussed.149
There are no data to support the use of cyclosporin in
breastfeeding because therapeutic blood concentrations in
the breastfed infant are described.150 It is not known
whether thalidomide is excreted in breast milk.
In 4 women treated with IFX while breastfeeding, the IFX
antibody could not be detected in breast milk and the IFX was
also not detectable in the sera of 3 infants.151,152
ADA has been reported to be excreted in low levels in the
milk of a nursing mother; however no data are available
about serum levels in infants.1537. Special considerations
7.1. Influence of IBD on sexualityECCO Statement 7 A
Data on the effect of IBD on the sexual function are
conflicting [EL4 RG C]. A negative effect on sexual
function is associated with low mood, but disease
activity is also implicated [EL4 RG C]. In males and
females sexual function seems to be preserved or even
increased after surgery [EL 2a, RG B].
There are conflicting data of the impact of IBD of
sexuality.154,155 It is likely that symptoms and disease activity
can affect sexuality, and female patients with IBD are
reported to have a higher likelihood of symptoms such as
penetration pain, low libido, andmenstrual abnormalities.156
Psychological factors may also play a role and depression has
been found to be more prevalent among people with IBD157
and is a predictor for low sexual function.158 Women with IBD
report significantly reduced sexual activity and libido
compared to men.159 There is conflicting evidence on the
affect of surgery on the sexual function of women with IBD
with some studies reporting a significant reduction in libido,
body image and sexual activity after surgery160; and otherUnknown safety Contraindicated
Metronidazole Methotrexate
Ciprofloxacin Thalidomide
Budesonide Cyclosporin
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dyspareunia.159–161 In men, sexuality seems to be less
affected.158,161 Rare complications, from particularly pelvic
surgery, include loss or retrograde ejaculation, however,
sexual function seems to be preserved or even increased after
surgery.161–163 This can be attributed to improvements in
general health after therapeutic surgery and/or improve-
ments in psychosexual health leading to increased sexual
desire following, for example, reversal of stoma which has
been shown to have a negative impact on sexual
function.164,1657.2. Oral contraceptive use in IBDECCO Statement 7 B
There are no data to support an effect of IBD on the
efficacy of oral contraceptives [EL4 RG D]. Oral
contraceptives do not aggravate the activity of IBD
[EL3B RG C].
There are no studies assessing the efficacy of oral
contraceptives (OCs) in women with IBD. OC steroids are
mainly absorbed from the small bowel, and contraceptive
efficacy depends on its absorptive capacity. Enhanced
passage of gastrointestinal contents or impaired absorption
may thus contribute to contraceptive failures in patients who
have chronic inflammatory disease, diarrhea, or jejunoileal
bypass. Therefore it can be hypothesized that the efficacy of
OCs may be reduced in women with CD who have small bowel
disease and malabsorption. The general advice for women
using OCs that have been vomiting or severe diarrhoea for
more than 24 h is to follow instructions for missed pills.166
One large prospective cohort study and some case-control
studies showed no effect of OCs on the activity of IBD.166–169ECCO Statement 7 C
IBD is a thrombophilic condition however the effect is
modest [EL3B RG C]. Oral contraceptives place
patients with thrombophilic conditions such as IBD
and smoking at higher risk for thromboembolism
[EL1B RG A]. Contraception is highly efficient and
safe in preventing unwanted pregnancy. In an IBD
patient a clinical decision regarding the use of contra-
ceptives should be made on an individual basisUsingOCs has longbeen associatedwith amodest increase in
the chance of developing IBD, specifically CD.170 In the older
literature a hypothesis was raised that OCs may play a role in
the etiology of IBD through a process of multifocal, microvas-
cular gastrointestinal infarction.171 Evidence regarding the
effect of thrombosis risk thatwould be specific to IBDpatients is
vague. Hormonal therapy is one of the most significant
prothrombotic risk factors. OCs induce resistance to activated
protein C,172 increase levels of procoagulant proteins (factors
II, VII, VIII, and fibrinogen),173 decrease levels of antithrombin,
protein S, tissue factor pathway inhibitor, and fibrinolyticproteins; and increase markers of coagulation and fibrinolysis
activation.173–175 The thrombotic risk associated with OC use
varies with the time interval since starting treatment but is
highest in the first year of use, especially in women who have a
prothrombotic defect.175,176 Adolescent girls who have coex-
isting thrombophilic conditions, such as systemic lupus erythe-
matosus, a history of thromboembolism (TE), or other
conditions, have relative contraindications to combination
hormonal contraceptive methods, because these medications
place them at higher risk for TE.177–180 Inflammation is a
thrombophilic condition, due to elevated factor VIII. IBD
specifically is considered a thrombophilic condition.181 Thus,
in an IBD patient a clinical decision regarding the use of OCs
should be made on an individual basis.
7.3. Venous thromboembolism risk in pregnancyECCO Statement 7 D
Risk assessment for VTE should be performed in the
pregnant patient with IBD [EL 4 RGC] Consideration of
prophylactic low molecular weight heparin should be
given for any pregnant IBD patient experiencing a
relapse, admitted to hospital or if additional risk
factors are identified [EL3 RG B].
Pregnancy increases the risk of venous thromboembolism
(VTE) by 4–6 fold182 and is a leading cause of direct maternal
death in developed countries.183 The timeof highest risk is in the
first 6 weeks of the postnatal period.184 IBD patients, particu-
larly hospitalised with active disease, are at increased risk for
VTE.185,186 Hospitalised pregnant IBD patients have an increased
risk of VTE compared to their non-IBD pregnant controls; for CD
aOR, 6.12 (95% CI, 2.91–12.9) and for UC an OR, 8.44 (95% CI,
3.71–19.2). Low molecular weight heparin in a prophylactic
dose reduces the risk of VTE in medical and surgical patients by
60–70%.187 Lowmolecular weight heparin has been shown to be
safe and efficacious in the pregnant population.188 Therefore
consideration of the use of prophylactic low molecular weight
heparin is pregnant IBD patients experiencing a relapse and/or
admitted to hospital, is strongly recommended. All women
should undergo a documented assessment of risk factors for
venous thromboembolism (VTE) in early pregnancy or before
pregnancy. This assessment should be repeated if the woman is
admitted to hospital for any reason and again after delivery.189
7.4. Cervical cancer screeningECCO Statement 7 E
It is imperative that all women with IBD utilize their
national screening programmes and ensure they have
regular (as per national guideline) surveillance [EL 2a
RG B]. Humane papilloma virus vaccination should be
given to all women with IBD, ideally prior to starting
immunosuppression [EL 5 RG D].
There is evidence of an increase in incidence of humane
papillomavirus (HPV)-associated cervical dysplasia in the renal
503European evidenced-based consensus on reproduction in inflammatory bowel diseasetransplant population190,191 and cervical intra-epithelial neo-
plasia (CIN) in human immunodeficiency virus (HIV)
patients.192 Therefore it has been extrapolated that women
with IBD who are on immunomodulatory therapy maybe at
similar risk.193,194 There is conflicting data to support this
assumption. Evidence for a higher incidence of cervical
dysplasia was demonstrated in an age-matched case con-
trolled study where 18% of womenwith IBDwere found to have
abnormal Pap smears compared to 5% of controls.195 This was
confirmed by another case controlled study which found
abnormal Pap smears in 42.5% of women with IBD compared to
7% of age and parity-matched controls (Pb0.001) 196. This
study implicated immunosuppressive therapy by showing an
increased incidence in abnormal Pap smears in those on
immunomodulators for N6 months compared to those not
taking such agents (OR 1.5 (1.2–7.1, P=0.021). Immunomo-
dulators were again implicated in a large retrospective case-
controlled study which showed higher hazard ratio with
increasing numbers of medications.197 However, the increase
in cervical dysplasia in these studies did not translate to an
increase in cervical neoplasms. More recently 2 large case-
controlled studies showed no increase in cervical dysplasia
associated with IBD with or without immunosuppressive
therapy.198,199 The only significant predictor of cervical
dysplasia in this population was current smoking (OR2.95, CI
1.55–5.50, P=0.001).198 While there is no consensus on the
necessary frequency of Pap smears, it is imperative that
women with IBD are counselled about the potential risks and
receive regular screening as per the national guideline. Many
countries have now adopted a policy of universal vaccination
for the certain types of HPV virus that are associated with 70%
of cervical cancers.200 It is therefore reasonable that women
with IBD, in particular should be advised to have this
vaccination, ideally before starting immunosuppressant ther-
apy.200 See for further recommendations ECCO statement OI
4E in Consensus on the prevention, diagnosis andmanagement
of infections in inflammatory bowel diseases.201
7.5. Endoscopy during pregnancyECCO Statement 7 G
Gastroscopy [EL3b RG B], sigmoidoscopy/colonoscopy
andERCP [EL4RGC] are generally considered tobe safe
in pregnancy, however, these procedures should only
be donewhen there is a strong indication and should be
performed in the second trimester whenever possible
[EL5 RG D]. Haemostasis measures are safe and should
be carried out with precautions [EL3, RG C].
ECCO Statement 7 H
Procedure time and radiation exposure should be kept to
a minimum [EL4 RG C]. Endoscopic procedures should
be managed in conjunction with specialists in obstetrics
and obstetric anesthesia [EL5 RG D]. Pregnant patients
should be placed in left pelvic tilt or left lateral position
before, during and after the endoscopic procedure, to
avoid vena caval compression [EL5 RG D]. Presence of
fetal heart sounds should beconfirmedbefore sedation is
begun and after the endoscopic procedure [EL5 RG D].ECCO Statement 7 I
Close attention should be paid to appropriate drug
selection using drugs most tried and tested in
pregnancy and using the minimum dose possible to
achieve the desired effect [EL4 RG C]. Sedative drugs
should be administered to provide patient comfort,
while avoiding over sedation [EL 5, RG D].
Limited evidence exists regarding the utility and safety of
endoscopy in the pregnant woman with IBD. Maternal
considerations include the increased risk of aspiration follow-
ing gastroscopy (OGD) due to lower oesophageal sphincter
incompetence. Fetal considerations include the preservation
of adequatematernal oxygenation and blood pressure to allow
optimal placental perfusion. Therefore pregnant women
undergoing endoscopy should have their saturationsmonitored
throughout the procedure and the minimum dose of sedating
drug necessary for an adequate effect should be used.
Pregnant patients in the 2nd or 3rd trimester should be placed
in the left pelvic tilt to reduce the risk of vena caval
compression and thus minimize hypotension. Due to these
potential complications, endoscopy in pregnancy should be
reserved for strong indications however; endoscopy does
appear to offer a relatively safe alternative to radiologic or
surgical intervention.202–205 Case series and case-controlled
studies have shown that OGD is safe and effective, with no
evidence for this procedure inducing labour.206,207 Likewise,
small case series of colonoscopy in pregnancy showed no
evidence of adverse outcome.208,209
Endoscopic retrograde cholangiopancreatography (ERCP) in
pregnancy has been reported in several case series.210–212
These studies suggest that ERCP is safe in pregnancy with no
increased incidence of congenital malformations, fetal dis-
tress or incidence of precipitating labour. However, there may
be a higher risk of post-ERCP associated pancreatitis,210,213–215
although this did not alter the overall pregnancy outcome in
these studies. Radiation dose should clearly be kept to a
minimum and in the majority of studies the dose did not
exceed the accepted threshold of 10 mGy however this was
not always the case and recently several case reports and a
small study on 6 pregnant women has described the successful
application of ERCP without radiation.216
The benefit of epinephrine, electricity and contrast
dye217 in the appropriate situation outweigh the risks.
The risk of use of polyethelene glycol for preparation is
considered low.218 Sodium phosphate preparations have no
data but a potential harm and should be avoided.219
7.5.1. Sedation
Meperidine is commonly used in endoscopy for analgesia and
sedation. It is rapidly transferred across the placenta but two
large studies of 268 mothers220 and 62 newborns,221
respectively; no teratogenicity from meperidine administra-
tion during the first trimester was reported. Meperidine can
cause diminished foetal beat-to-beat cardiac variability that
lasts for approximately 1 h after maternal intravenous
administration.222 This can also be interpreted as a sign of
foetal distress; however this side effect is reversible,
transient, and not a poor prognostic indicator. Meperidine,
when used sparingly, is approved by the American Academy
of Pediatrics for use in breast-feeding mothers.
Figure 1 Algorithm for counseling females who wish to conceive.
504 C.J. van der Woude et al.Fentanyl is commonly administrated during labour and is
considered safe although case reports note neonatal respira-
tory depression, muscle rigidity,223 and opioid withdrawal224
as potential side effects. Fentanyl is excreted in breast milk,
but its low bioavailability to the breast-feeding infantmakes it
acceptable to breast-feed following its use.225
Propofol use during endoscopy is increasingly common.
However, it has not been extensively studied in women in the
first and second trimesters and therefore is not recom-
mended for use during this time. Small amounts of propofol
are excreted into breast milk and colostrum, but the
concentration is considered negligible.226
The benzodiazepines, diazepam and midazolam should be
avoided particularly during the first trimester. Midazolam,
the preferred benzodiazepine for endoscopy, crosses the
human placenta, but fetal serum levels increase to only
about one to two thirds of maternal serum levels after oral,
intramuscular, or intravenous maternal administration.
Midazolam and its metabolite are excreted into milk, but
there is minimal exposure if breast-feeding was held for 4 h
after administration of a 15 milligram dose.226,227
8. Recommendations from the consensus groupECCO Statement 8 A
Appropriate referral for pre-pregnancy and pre-con-
ception counseling should be available for all patients
with IBD to advise and optimise management before
conception [EL5 RG D].
ECCO Statement 8 B
If steroids and biological therapy is required in third
trimester, women should receive multidisciplinary care
by a team with experience in treating active IBD in
pregnancy [EL5 RG D].It was shown in a small case series that the majority of IBD
patients with conception plans require medication for which
limited information on the safety of the peri-conceptional
use is available.228 In addition, reproductive wish lead to the
medication changes in one third of these patients. Therefore
the working group feel it is important to counsel all IBD-
patients wishing to conceive (see for suggested algorithm in
females; Fig. 1). Furthermore if a flare occurs in the third
trimester the working group feels that these women are in
need of specialized multidisciplinary care by a team with
experience in treating active IBD in pregnancy. This team
should include gastroenterologists, obstetricians and
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